Contact A Representative Xolair® Omalizumab
The committee pointed out that some clinical trial failures resulted in a “disappointing share cost development.” But, general, the committee was very pleased with Narasimhan’s overall performance. 5 years right after my executive team and I debated how to focus our strategy and moved forward to execute on this three-pronged plan, our efforts are beginning to spend off. The pharmaceuticals division management team that was named after I became the CEO of Novartis, in 2010, has carried out an outstanding job of offsetting the Diovan patent cliff. We’ve told Wall Street analysts that we count on 2012 income to be...